Vivakor, Inc. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Vivakor, Inc., a trans-disciplinary biomedical company based in Coralville, Iowa. The report covers the three-month period ended March 31, 2010. The company focuses on the discovery, development, and commercialization of medical devices, pharmaceuticals, and nutraceuticals. It operates as a "smaller reporting company" and is currently in a development stage with limited commercial revenue.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenue | $161,310 | $6,223 |
| Gross Profit | $53,451 | $1,942 |
| Net Loss | $(591,293) | $(505,237) |
| Net Loss Attributable to Vivakor | $(557,161) | $(500,246) |
| Cash and Cash Equivalents (End of Period) | $17,791 | $20,990 |
| Net Cash Used in Operating Activities | $(262,855) | $(116,679) |
| Total Current Liabilities | $1,866,933 | $2,216,301 |
| Stockholders' Equity (Total) | $489,255 | $60,375 |
Liquidity and Debt: As of March 31, 2010, the company held $17,791 in cash. Significant liabilities include $918,318 in accrued wages, $510,056 in a note payable related to the HealthAmerica acquisition, and $110,721 in convertible notes payable. The company has a substantial accumulated deficit of $(3,977,822).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly to $161,310 from $6,223 in the prior year. This was driven by product sales of $135,650 and license fees of $25,660, all derived from a new license agreement with Regeneca International, Inc. for the VivaBoost product.
- Expense Increases: General and administrative expenses surged to $428,581 from $143,735. This increase was primarily due to higher consulting fees ($201,350 vs. $2,910), increased stock-based compensation ($47,672 vs. $0), and higher legal/accounting fees due to active trading and SEC filing requirements.
- Operating Loss: Despite revenue growth, the loss from operations widened to $(651,553) from $(439,205) due to the sharp rise in operating expenses.
- Debt Restructuring: The company offset $238,620 in advances payable to stockholders with notes receivable and converted a $108,849 note payable into 837,301 shares of common stock.
Outlook, Risks, and Management Commentary
Going Concern: Management and the independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. The company does not have sufficient cash on hand to fund operations for the next twelve months. Continued existence depends on obtaining additional financing through debt, equity, or strategic partnerships.
Capital Formation: The company is in the midst of a capital formation activity (effective August 2009) to raise up to $3.45 million. As of March 31, 2010, it had received $319,714 in net cash proceeds and issued shares in exchange for notes receivable totaling $1.34 million. However, the notes receivable are on a month-to-month extension with no assurance of collection.
Defaults: The company is in arrears on a $510,056 note payable related to the HealthAmerica acquisition, which requires monthly payments of $25,000. No action has been taken by the note holder (a related party) to date. In May 2010, the company agreed to convert $331,000 of this note into common stock.
Subsequent Events: Following the quarter end, the company issued additional shares to consultants and entered into two new convertible promissory notes totaling $57,500.
Investor Verification Checklist
- Cash Runway: Verify the company's immediate ability to pay accrued wages ($918k) and operating expenses given cash reserves of only $17,791.
- Debt Conversion: Confirm the status of the $510k HealthAmerica note default and the terms of the May 2010 conversion agreement.
- Related Party Transactions: Review the concentration of revenue (100% from Regeneca) and the nature of the $1.34 million in notes receivable from stockholders/related parties.
- Capital Raise Progress: Assess the likelihood of collecting the remaining balances on the notes receivable issued in the capital formation activity.
- Stock Dilution: Monitor the impact of recent and planned share issuances for services and debt conversion on existing shareholders.